Document is current

Article History

Received: 26 April 2024

Accepted: 4 October 2024

First Online: 6 November 2024

Declarations

:

: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and did not receive payment related to the development of this podcast article. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Charles C. Wykoff reports receiving: consulting fees/honoraria for ongoing services provided for 4DMT, AbbVie, Adverum, Alcon, Alimera, Annexon, Apellis, Ascidian, Aviceda, Bayer, Biocryst, Boehringer Ingelheim, Curacle, Emmecell, EyeBiotech, EyePoint, Genentech, InGel, Iveric Bio, Janssen, Kiora, Kodiak, Merck, Merit, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, ONL, Opthea, Osanni, Oxular, Perceive Bio, Perfuse, Ray, Regeneron, RegenXBio, Roche, Sandoz, Sanofi, Santen, Stealth, Thea, Valo, Visgenx and Zeiss; grants for ongoing research support as a Principal Investigator for trials sponsored by: 4DMT, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, Asclepix, Aviceda, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, EyeBiotech, EyePoint, Genentech, Gyroscope, IONIS, Iveric Bio, Janssen, Kodiak, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, OcuTerra, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Regeneron, RegenXBio, Rezolute, Roche, Stealth, Skyline and Valo; and stock investments in: InGel, ONL, Osanni, Panther, PolyPhotonix, RecensMedical, TissueGen, Visgenx and Vitranu. Stela Vujosevic reports receiving consulting fees from AbbVie, Apellis, Bayer, Boehringer Ingelheim, Novartis, Roche and Zeiss. Daniel Newman has received payment for one-off speaking engagements from Roche, Sanofi and Boehringer Ingelheim and is a patient ambassador for Abbott and Insulet. Bernadette Warren has participated in small projects with Bayer, AbbVie and Roche that are unrelated to this publication. Randall Barker has no conflicts of interest to declare.

: This article is based on opinions and previously conducted studies and does not mention any new studies with human participants or animals performed by any of the authors.